Candorium Free Members
Join Candorium to access the full article and more
Free Member Benefits:
✔
Comment & Reply✔
Newsletter Access✔
Follow Authors✔
Share via SMS Go Back
Inhibrx, Inc. revenue decreases to $17,000 in quarter ended Mar 31, 2023 from previous quarter
By USInMinutes - May 08, 2023, 11:36 PM ET
Last Updated - Jul 18, 2023, 03:33 PM EDT
Key fundamental financials- loss of $48.92 million
- Revenue of $17,000
| Current Reporting | Revenue | Net Income | Profit/Loss |
|---|---|---|---|
| Mar 2023 | $17,000 | $48.92 million | loss |
| Sep 2022 | $278 | $35,325 | loss |
| Jun 2022 | $711,000 | $37.73 million | loss |
Inhibrx, Inc. [INBX] has reported $48.92 million loss for the fiscal quarter ending Mar 31, 2023.
Revenue for the quarter was $17,000 with operating income of $43.77 million.
The Lajolla, California (CA)-based company operating in the biological products, except diagnostic substances sector has total shareholders equity of $15.13 million.
Also read:
This is a developing story. Click here to receive updates.
------------
NewsInMinutes, an offering of 10kInfo, Inc., brings you news on the latest regulatory filings. Subscribe to additional news alerts here.
Sponsored
Read More from Quarterly Reports
Read More from USinMinutes
Popular News
Latest News
